Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLCGiulia Mazzaschi, Cristina Marrocchio, Lucas Moron Dalla Tor, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2023
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE studyMelissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapyAndrea De Giglio, Alessandro Leonetti, Francesca Comito, et al.
JCO Precision Oncology|June 12, 2026
Liquid Biopsy Monitoring in <i>BRAF</i> V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)Alessandro Leonetti, Monica Pluchino, Roberta Minari, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Tumori|May 10, 2018
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocolAndrea Casadei Gardini, Luca Faloppi, Giuseppe Aprile, et al.
Cancer Discovery|August 5, 2025
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapySimon Baldacci, Elliott J Brea, Francesco Facchinetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinibAlessandro Di Federico, Federica Pecci, Mark Jeng, et al.
Tumori|May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world studyAlessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
Pageof 7